Oncology medicine spending at list prices vs Oncology novel active substance (NAS) launches (cumulative)

Oncology medicine spending at list prices and Oncology novel active substance (NAS) launches (cumulative) worldwide, compared over time.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.

Oncology medicine spending at list prices

Unit: billion USD · 2 observations

Line chart

Forecast: dashed line, hollow markers, shaded band

Oncology medicine spending at list pricesOncology medicine spending at list prices. 2 observations from 2024 to 2029, ranging from 252 billion USD to 441 billion USD, of which 1 are forecasts. Latest value 441 billion USD (2029). billion USD 0 100 200 300 400 500 2005 2009 2013 2017 2021 2025 2029 FORECAST 252 441
Oncology medicine spending at list pricesOncology medicine spending at list prices. 2 observations from 2024 to 2029, ranging from 252 billion USD to 441 billion USD, of which 1 are forecasts. Latest value 441 billion USD (2029). billion USD 0 100 200 300 400 500 2005 2009 2013 2017 2021 2025 2029 FORECAST 252 441
Oncology medicine spending at list pricesOncology medicine spending at list prices. 2 observations from 2024 to 2029, ranging from 252 billion USD to 441 billion USD, of which 1 are forecasts. Latest value 441 billion USD (2029). billion USD 0 100 200 300 400 500 2005 2009 2013 2017 2021 2025 2029 FORECAST 252 441
View the underlying data
Oncology medicine spending at list prices
Period Type Value
2024 Actual 252 billion USD
2029 Forecast 441 billion USD
Source: IQVIA · CC BY 4.0 · Full series

Oncology novel active substance (NAS) launches (cumulative)

Unit: count · 3 observations

Line chart
Oncology novel active substance (NAS) launches (cumulative)Oncology novel active substance (NAS) launches (cumulative). 3 observations from 2005–2024 to 2020–2024, ranging from 79 to 282. Latest value 132 (2020–2024). 0 100 200 300 2005 2009 2013 2017 2021 2025 2029 282 132
Oncology novel active substance (NAS) launches (cumulative)Oncology novel active substance (NAS) launches (cumulative). 3 observations from 2005–2024 to 2020–2024, ranging from 79 to 282. Latest value 132 (2020–2024). 0 100 200 300 2005 2009 2013 2017 2021 2025 2029 282 132
Oncology novel active substance (NAS) launches (cumulative)Oncology novel active substance (NAS) launches (cumulative). 3 observations from 2005–2024 to 2020–2024, ranging from 79 to 282. Latest value 132 (2020–2024). 0 100 200 300 2005 2009 2013 2017 2021 2025 2029 282 132
View the underlying data
Oncology novel active substance (NAS) launches (cumulative)
Period Type Value
2005–2024 Actual 282
2015–2019 Actual 79
2020–2024 Actual 132
Source: IQVIA · CC BY 4.0 · Full series

Provenance

Where these numbers come from

Oncology medicine spending at list prices

Total spending on cancer medicines valued at list prices.

2 observations in Global · source organisations: IQVIA

Oncology novel active substance (NAS) launches (cumulative)

Total number of oncology novel active substances launched over a stated multi-year period.

3 observations in Global · source organisations: IQVIA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related